Djin Lai1,2, Qian Ding3, Julia Bodson1, Echo L Warner1,2, Deanna Kepka1,2. 1. Cancer Control and Population Sciences, Huntsman Cancer Institute, Salt Lake City, Utah. 2. College of Nursing, University of Utah, Salt Lake City, Utah. 3. Study Design and Biostatistics Center, School of Medicine, University of Utah, Salt Lake City, Utah.
Abstract
OBJECTIVE: This study sought to examine sociodemographic factors surrounding human papillomavirus (HPV) vaccine initiation and three-dose completion rates in the Intermountain West (IW). DESIGN AND SAMPLE: Analysis of the Centers for Disease Control and Prevention's 2012 National Immunization Survey-Teen dataset was conducted with a survey-weighted Pearson chi-square test and multivariable Poisson regression to produce bivariate and multivariate analyses. Participants with daughters aged 13-17 with provider-verified immunization records were included. Dual-frame adjusted prevalence ratios (PR) and 95% confidence intervals (CI) were produced with provider-phase sampling weights. MEASURES: Factors included parents' and adolescents' sociodemographic and healthcare usage variables. Outcome measures included adolescents' receipt and completion of the HPV vaccine. RESULTS: Older parental ages (45 years and above) showed lower prevalence of adolescent HPV vaccine initiation (PR = 0.73, 95% CI = 0.59-0.87, p = .003) and completion (PR = 0.65, 95% CI = 0.44-0.96, p = .031) compared with parents younger than 35. Seventeen-year-old adolescents demonstrated highest prevalence of initiating (PR = 1.88, 95% CI = 1.47-2.39, p < .001) and completing (PR = 2.92, 95% CI = 1.97-4.33, p < .001) the vaccination series compared to 13-year olds. Those who had received meningitis vaccinations had high prevalence of initiating (PR = 1.93, 95% CI = 1.50-2.48, p < .001) and completing the HPV vaccine (PR = 2.52, 95% CI = 1.64-3.86, p < .001). CONCLUSION: This study highlights parental, adolescent, and health care characteristics related to use of the HPV vaccine. Future research to investigate specific barriers and strategies for addressing HPV vaccination use in the IW is recommended.
OBJECTIVE: This study sought to examine sociodemographic factors surrounding human papillomavirus (HPV) vaccine initiation and three-dose completion rates in the Intermountain West (IW). DESIGN AND SAMPLE: Analysis of the Centers for Disease Control and Prevention's 2012 National Immunization Survey-Teen dataset was conducted with a survey-weighted Pearson chi-square test and multivariable Poisson regression to produce bivariate and multivariate analyses. Participants with daughters aged 13-17 with provider-verified immunization records were included. Dual-frame adjusted prevalence ratios (PR) and 95% confidence intervals (CI) were produced with provider-phase sampling weights. MEASURES: Factors included parents' and adolescents' sociodemographic and healthcare usage variables. Outcome measures included adolescents' receipt and completion of the HPV vaccine. RESULTS: Older parental ages (45 years and above) showed lower prevalence of adolescent HPV vaccine initiation (PR = 0.73, 95% CI = 0.59-0.87, p = .003) and completion (PR = 0.65, 95% CI = 0.44-0.96, p = .031) compared with parents younger than 35. Seventeen-year-old adolescents demonstrated highest prevalence of initiating (PR = 1.88, 95% CI = 1.47-2.39, p < .001) and completing (PR = 2.92, 95% CI = 1.97-4.33, p < .001) the vaccination series compared to 13-year olds. Those who had received meningitis vaccinations had high prevalence of initiating (PR = 1.93, 95% CI = 1.50-2.48, p < .001) and completing the HPV vaccine (PR = 2.52, 95% CI = 1.64-3.86, p < .001). CONCLUSION: This study highlights parental, adolescent, and health care characteristics related to use of the HPV vaccine. Future research to investigate specific barriers and strategies for addressing HPV vaccination use in the IW is recommended.
Authors: Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman Journal: J Natl Cancer Inst Date: 2015-04-29 Impact factor: 13.506
Authors: Sharon J M Kessels; Helen S Marshall; Maureen Watson; Annette J Braunack-Mayer; Rob Reuzel; Rebecca L Tooher Journal: Vaccine Date: 2012-04-03 Impact factor: 3.641
Authors: Harrell W Chesson; Donatus U Ekwueme; Mona Saraiya; Meg Watson; Douglas R Lowy; Lauri E Markowitz Journal: Vaccine Date: 2012-08-04 Impact factor: 3.641
Authors: Gina S Ogilvie; Valencia P Remple; Fawziah Marra; Shelly A McNeil; Monika Naus; Karen L Pielak; Thomas G Ehlen; Simon R Dobson; Deborah M Money; David M Patrick Journal: CMAJ Date: 2007-12-04 Impact factor: 8.262
Authors: F Xavier Bosch; Thomas R Broker; David Forman; Anna-Barbara Moscicki; Maura L Gillison; John Doorbar; Peter L Stern; Margaret Stanley; Marc Arbyn; Mario Poljak; Jack Cuzick; Philip E Castle; John T Schiller; Lauri E Markowitz; William A Fisher; Karen Canfell; Lynette A Denny; Eduardo L Franco; Marc Steben; Mark A Kane; Mark Schiffman; Chris J L M Meijer; Rengaswamy Sankaranarayanan; Xavier Castellsagué; Jane J Kim; Maria Brotons; Laia Alemany; Ginesa Albero; Mireia Diaz; Silvia de Sanjosé Journal: Vaccine Date: 2013-12-30 Impact factor: 3.641
Authors: Djin Lai; Julia Bodson; France A Davis; Doriena Lee; Fahina Tavake-Pasi; Edwin Napia; Jeannette Villalta; Valentine Mukundente; Ryan Mooney; Heather Coulter; Louisa A Stark; Ana C Sanchez-Birkhead; Deanna Kepka Journal: J Community Health Date: 2017-04
Authors: Mary A Gerend; Yesenia P Stephens; Michelle M Kazmer; Elizabeth H Slate; Elena Reyes Journal: J Adolesc Health Date: 2019-02-15 Impact factor: 5.012
Authors: Rose Gunn; Laura K Ferrara; Caitlin Dickinson; Isabel Stock; Jennifer Griffith-Weprin; Amy Wiser; Brigit Hatch; L J Fagnan; Patricia A Carney; Melinda M Davis Journal: Am J Prev Med Date: 2020-06-27 Impact factor: 5.043
Authors: Echo L Warner; Qian Ding; Lisa Pappas; Julia Bodson; Brynn Fowler; Ryan Mooney; Anne C Kirchhoff; Deanna Kepka Journal: JMIR Cancer Date: 2017-08-11